1

Molecular Modeling and Drug Design

Monalisa Kesh[1], Abhirup Ghosh[2], and Diptanil Biswas[3]

[1] *Centre for Digital Health, Indian Institute of Technology Bombay, Mumbai, India*
[2] *School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India*
[3] *Department of Statistical Genomics, National Institute of Biomedical Genomics, Kalyani, West Bengal, India*

1.1 Introduction

1.1.1 What Is Molecular Modeling?

Molecular modeling is at the cutting edge of scientific innovation and discovery, providing a paradigm-shifting method for comprehending the microscopic world of atoms and molecules. Researchers in various disciplines, including chemistry, biology, materials science, and pharmacology, are given newfound strength by this computational technique that enables them to precisely model, examine, and forecast the behavior of molecules and molecular systems. At its core, molecular modeling uses computers' computational capacity to reveal the nanoscale world's well-kept secrets, providing knowledge that is essential for expanding our understanding of the natural world and fostering technological advancements [1]. The attraction of molecular modeling is its capacity to connect theory and experiment. It offers a comprehensive understanding to the researchers to examine the dynamics of large molecular assemblies, the creation of chemical bonds, and the delicate description of atoms. Researchers can now examine issues that are frequently difficult, expensive, or even impractical to solve using only conventional experimental methods but much easier by this computational playground [2].

The significance of molecular modeling is most notable in drug development, where it has completely changed how pharmaceutical molecules are created and optimized. Researchers can quickly screen and prioritize prospective treatments by modeling the interactions between drug candidates and their target proteins, considerably speeding up the drug development process. This has contributed to personalized medicine, in which treatments are matched to specific genetic profiles as well as the development of novel therapeutics. The design of novel materials with specific features is aided in materials research by molecular modeling. Computational modeling directs the development of materials for various applications, from electronics to aerospace, whether it is optimizing the structure of innovative polymers, investigating the behavior of sophisticated composites, or comprehending the properties of nanomaterials [3, 4].

Beyond these areas, molecular modeling provides a flexible tool for understanding chemical processes, researching the principles of protein folding, and evaluating environmental effects. It is essential to education because it aids in the visualization of intricate molecular relationships and

Computational Methods for Rational Drug Design, First Edition. Edited by Mithun Rudrapal.

structures, which deepens comprehension of the underlying ideas that control the natural world. By enabling researchers to solve the riddles of molecules and molecular systems, molecular modeling acts as a light of scientific discovery in this era of computational inquiry, advancing us to new horizons of knowledge and innovation [5].

1.1.2 Software Used for Molecular Modeling

In the discipline of molecular modeling, software is crucial because it allows researchers to carry out intricate simulations, see molecular structures, and quickly process data. There are numerous software programs accessible, each suited to particular modeling methodologies and study goals [6]. These famous applications are frequently used for molecular modeling.

1.1.2.1 Schrodinger

For molecular modeling and drug development, Schrodinger provides a complete range of software tools. A user-friendly interface is offered by Maestro, one of its flagship products, for various modeling activities, including molecular dynamics (MD) simulations, virtual screening, and structure-based drug creation [7].

1.1.2.2 GROMACS

GROMACS is a potent simulation tool for MD that is typically employed to examine the behavior of biomolecules like proteins and lipids. It is a well-liked option in both academia and business because of its speed and scalability [8].

1.1.2.3 Amber

Amber is a second extensively used program for modeling MD, with a significant emphasis on biomolecular systems. It is appropriate for various research applications since it has tools for modeling proteins, nucleic acids, and tiny compounds [9].

1.1.2.4 CHARMM

Known for its prowess in simulating intricate biomolecular systems and researching protein–ligand interactions, CHARMM (Chemistry at HARvard Molecular Mechanics) is a leading name in the field. Drug discovery and structural biology both make substantial use of it [10].

1.1.2.5 AutoDock

A well-liked molecular docking program, AutoDock, forecasts how tiny compounds will interact with protein receptors. It is useful for identifying prospective medication candidates during virtual screening [11].

1.1.2.6 VMD

The versatile molecular visualization program VMD (visual molecular dynamics) is used to examine and display molecular structures, trajectories, and data from numerous simulation programs. It is especially helpful for producing gorgeous molecular graphics [12].

1.1.2.7 PyMOL

PyMOL is a popular molecular visualization program that provides an easy-to-use interface for developing professional-grade 3D molecular images and animations. It is helpful for both academic and research endeavors [13].

1.1.2.8 Open Babel

A useful tool for data preparation and software package compatibility, Open Babel, is an open-source chemical toolkit that enables users to convert between multiple chemical file formats [14].

1.1.2.9 Avogadro

Avogadro is a user-friendly, open-source tool for building and analyzing molecular structures. It is a molecular editor and visualization tool [15].

1.1.2.10 Discovery Studio

Developed by BIOVIA (formerly Accelrys), Discovery Studio is a complete set of molecular modeling and simulation tools used in materials science and drug development [16].

To conduct cutting-edge molecular modeling studies, advance our understanding of molecular systems, and hasten discoveries in areas like drug development, materials science, and structural biology, these software tools are indispensable aids for researchers in various scientific disciplines. The unique study objectives, available computing power, and user skills all play a role in the software selection process.

1.1.3 Molecular Mechanics

Due to the invaluable insights of molecular mechanics into the interactions between medications and their biological targets, typically proteins, molecular mechanics plays a significant role in the development of new drugs. This computational method helps researchers identify and optimize prospective medication candidates by assisting in the study of the structural and energetic elements of molecular interactions. Here is how molecular mechanics assists in the search for new medicines [17].

1.1.3.1 Prediction of Binding Affinity

Molecular mechanics can calculate the binding affinity between a potential medication and its intended protein target. Researchers can forecast how tightly the medicine will bind to the target by estimating the potential energy of the drug–receptor combination. When choosing or creating molecules with higher affinity, which increases medicinal efficacy, this information is essential.

1.1.3.2 Conformational Analysis

Molecular mechanics that aids in the investigation of various conformations of a drug molecule may take up in the binding site of its target. This is important because proteins are dynamic structures, and knowing how a medicine interacts with different conformations might help formulators create more potent drugs.

1.1.3.3 Virtual Screening

To quickly assess the binding of hundreds of chemicals to a target protein, high-throughput virtual screening uses molecular mechanics. To find possible drug candidates, virtual screening makes use of molecular mechanics simulations, which optimize molecular interactions for effective drug discovery. The prioritization of compounds with favorable binding energies speeds up the identification of prospective therapeutic candidates [18].

1.1.3.4 Lead Discovery

Molecular mechanics helps refine lead compounds during drug development. It aids in the decision-making process for scientists when deciding whether chemical alterations will improve a drug's binding affinity, selectivity, and overall pharmacological qualities [19].

1.1.3.5 Mechanism of Action

Computer simulations of molecular mechanics shed light on the ways in which medicines affect their intended protein targets. By modeling molecular interactions, molecular mechanics

sheds light on drug processes and the finer points of a drug's mode of action. Researchers can use this information to create medications with more on-target effects and precise mechanisms of action. Absorption, distribution, metabolism, and excretion (ADME) and possible toxicity of drug candidates can also be predicted using molecular mechanics. Evaluation of a drug's safety and bioavailability is aided by knowledge of how it interacts with cellular and physiological elements [20].

In drug development, molecular mechanics is a crucial tool for logically designing and perfecting therapeutic medicines. Reducing the number of prospective candidates saves time and money for researchers while increasing the likelihood that successful medications with focused effects and few adverse effects will be developed.

1.2 Types of Molecular Models

Molecular models are critical in clarifying complicated structures at the molecular level, assisting both scientists and students in picturing three-dimensional (3D) atom configurations. Three important models stand out among the numerous types: the ball-and-spoke model, the space-filling model, and the crystal lattice model (Figure 1.1).

The ball-and-spoke model represents atoms as spheres and bonds as sticks, simplifying chemical structures. This basic method explains connectedness and geometry. In contrast, the space-filling model depicts atoms as spheres that occupy available space, displaying relative sizes and molecular packing. Crystal lattice models play an important role in crystallography because they depict the recurring atomic configurations in crystals while stressing symmetry and periodicity. These models, each with its own set of strengths, contribute to a full understanding of molecular structures by providing different viewpoints on the microscopic world [21, 22].



Figure 1.1 Different molecular models of carbon dioxide (CO_2). (a) Ball and stick model, (b) space-filling model, and (c) crystal lattice model.

1.2.1 Ball-and-Spoke Model

In molecular modeling, ball-and-spoke models are crucial visual representations that simplify the complex 3D structures of molecules for analysis and comprehension. This paradigm, which depicts atoms as spheres and bonds as sticks, has found widespread applicability in various scientific disciplines. The ball-and-spoke model, often known as the stick model, is a molecular depiction in which atoms are represented as spheres and the bonds that connect them as sticks. This straightforward approach visualizes molecular geometry in a practical and simple manner, assisting researchers in comprehending the spatial arrangement of atoms within a molecule [23].

Applications of this model:

- **Structural analysis**: The ball-and-spoke model is extensively used in structural elucidation because it allows researchers to easily determine bond angles, bond lengths, and overall molecular shapes.
- **Teaching tool**: The model is an effective teaching tool in educational settings, reducing complex chemical structures for pupils and facilitating a better understanding of key chemistry principles.
- **Communication**: The model is a universal language in scientific communication, commonly used to transmit molecular structures to varied audiences in research publications, presentations, and textbooks.

Pros of this model:

- **Simplicity**: The model's simplicity makes it approachable to both academics and students, promoting a clear understanding of molecular geometry.
- **Intuition**: The visual depiction aids in the rapid understanding of molecular structures, allowing for instant insights into atom connectivity and arrangement.
- **Communication effectiveness**: The ball-and-spoke paradigm promotes clarity in research publications and presentations, making it an effective means of communication in the scientific community.

Cons of this model:

- **Oversimplification**: In some circumstances, the model may oversimplify molecular activity, ignoring nuances that more advanced models may capture.
- **Electron density representation is limited**: The model does not directly express information regarding electron density or orbital features, which can be critical for a thorough understanding of molecular properties [23, 24].

1.2.1.1 Future Directions

As molecular modeling techniques advance, researchers are exploring ways to integrate the strengths of the ball-and-spoke model with more advanced computational methods, aiming for a more holistic representation of molecular structures.

In conclusion, the ball-and-spoke model remains a cornerstone in molecular modeling, offering a balance between simplicity and effectiveness. While it has its limitations, its widespread applications and continued use underscore its significance in the scientific community's pursuit of understanding molecular complexities.

1.2.2 Space-filling Models

Space-filling models, often known as CPK models (after the initials of the creators Corey, Pauling, and Koltun), describe molecules by portraying atoms as spheres with radii proportional to the van der Waals radii of the respective elements. These models try to provide a realistic representation of molecular structures by demonstrating how atoms pack together efficiently in 3D space [25, 26].

Applications of this model:

- **Steric considerations**: Space-filling models are very useful for comprehending steric hindrance and molecule packing. They explain how atoms inhabit space and impact the orientations of one another.
- **Drug design**: Space-filling models in pharmaceutical research help in drug design by visualizing how compounds can interact within active areas of biological macromolecules, allowing researchers to optimize binding interactions.
- **Molecular size visualization**: The models excel in conveying the relative sizes of atoms within a molecule, allowing for a better understanding of molecular dimensions and overall structure.

Pros of this model:

- **Steric considerations**: Space-filling models can help you understand steric hindrance and molecular packing. They describe how atoms inhabit space and influence one another's orientations.
- **Drug design**: In pharmaceutical research, space-filling models aid in drug design by visualizing how chemicals interact within active areas of biological macromolecules, allowing researchers to optimize binding interactions.
- **Visualization of molecular size**: The models excel in communicating the relative sizes of atoms within a molecule, allowing for a better comprehension of molecular dimensions and overall structure.

Cons of this model:

- **Complexity for large molecules**: Space-filling models for large and complicated molecules may appear cluttered, making it difficult to detect individual characteristics.
- **Inadequate bond information**: Space-filling models, unlike ball-and-spoke models, do not directly depict bond information, instead focus on atomic configurations [27].

1.2.2.1 Future Directions

Advances in processing power and visualization techniques provide opportunities to improve space-filling models. The incorporation of interactive and dynamic aspects may alleviate some of the difficulties involved with seeing complicated chemical structures.

Finally, space-filling models provide a detailed and realistic description of molecular structures, revealing important information about molecular size, steric effects, and overall packing. Despite significant limitations, their applications in various scientific disciplines highlight their importance as indispensable tools for both molecular modelers and researchers.

1.2.3 Crystal Lattice Models

In molecular modeling, crystal lattice models describe the repeated arrangement of atoms within a crystal structure. These representations highlight crystals' 3D periodicity, emphasizing the regular arrangement of atoms and molecules inside the lattice. These models help researchers grasp the relationship between microscopic arrangements and macroscopic features by offering a macroscopic picture of the crystalline structure [28].

Applications of this model:

- **Material science**: Crystal lattice models are important in materials science because they guide researchers in the discovery and design of novel materials. Predicting material qualities requires an understanding of the crystal structure.
- **Drug development**: Crystallography aids in the elucidation of the crystal structures of medicinal molecules in pharmaceutical research, providing critical information for optimizing medication formulation and increasing bioavailability.
- **Electronic properties**: In order to understand the electronic properties of semiconductors and other electronic materials, crystal lattice models are required [29, 30].

Pros of this model:

- **Periodic insight**: Crystal lattice models depict the periodic arrangement of atoms, allowing researchers to identify patterns and symmetries within the crystal lattice.
- **Macroscopic understanding**: These models bridge the gap between microscopic and macroscopic scales, providing a comprehensive view of the crystal structure and assisting with experimental data interpretation.
- **Predictive capability**: Understanding the crystal lattice is critical for forecasting material properties and driving the creation of novel materials with specific functions [31].

Cons of this model:

- **Oversimplification**: While crystal lattice models are excellent at depicting periodicity, they may oversimplify certain aspects of molecular activity, ignoring dynamic and nonperiodic processes.
- **Noncrystalline material complexity**: Because crystal lattice models are inherently intended for crystalline materials, their application for examining noncrystalline or amorphous structures is limited [31].

1.2.3.1 Future Directions

Crystal lattice models are becoming more useful as computational tools and experimental procedures advance. Integrating real-time simulations and dynamic elements could improve the accuracy and application of these models, allowing them to represent a wider range of materials.

Finally, crystal lattice models continue to be vital in molecular modeling, providing a powerful tool for understanding the periodicity and structure of crystalline materials. Their applications in materials science, drug development, and electronics highlight their value as valuable tools for researchers attempting to unravel the mysteries of molecular configurations in the solid state.

1.3 Computational Methods in Drug Discovery

1.3.1 What Is Drug Discovery?

By combining computational, mathematical, experimental, translational, and clinical models, possible novel medicinal entities can be identified through the process of drug development. It is the technique of locating and analyzing compounds that have the ability to govern illness in a secure way, with the aim of developing medications that can prolong patients' lives. Drug development is still an arduous, expensive, time-consuming, and ineffective process with a high dropout rate of novel therapeutic discovery, despite advancements in biotechnology and physiological system

understanding. Knowing a biological target while employing creativity to find novel drugs can be referred to as drug designing. Creating molecules that complement the molecular target they interact and bind to in terms of charge and shape is the fundamental aspect of drug design. In the big data era, drug design typically, but not always, depends on computer modeling tools and bioinformatics methodologies [32].

Apart from small molecules, biopharmaceuticals, particularly therapeutic antibodies, have emerged as a significant class of medications [33]. Significant progress has also been made in computational methods for enhancing the stability, selectivity, and affinity of these protein-based treatments. Preclinical research on animal and cell models as well as human clinical trials are all part of the process of developing and discovering new drugs. Afterward, the drug must receive regulatory approval before being put on the market. In contemporary drug discovery, screening hits are identified, medicinal chemistry is applied, and those hits are optimized to improve the hit's affinity, specificity, efficacy, metabolic stability, and oral bioavailability. Before conducting clinical trials, a molecule that satisfies all of these criteria will be found, and the drug development process will start [34].

An illness or clinical condition for which there are not any appropriate pharmaceuticals on the market leads to the start of a drug discovery program, and this unmet clinical need serves as the project's primary source of motivation. The preliminary study, which is frequently conducted in academic settings, produces information to support a hypothesis that a protein's or pathway's activation or inhibition will have a beneficial impact in the context of a medical condition. The result of this action is the identification of a target that, in order to support a drug development endeavor, may need additional validation before moving forward into the lead discovery phase. It is a drawn-out, resource-intensive procedure that calls for close collaboration among various disciplines. The pharmaceutical industry is extremely interested in optimizing the drug discovery process since identifying and selecting appropriate drug candidates promptly can have a significant impact on the price and profitability of new medications [35, 36].

1.3.2 Computational Platforms for Drug Discovery

In the field of drug development, computational platforms and algorithms are invaluable resources that have revolutionized the conventional and tedious approaches. These tools utilize artificial intelligence (AI), chemical simulations, and advanced algorithms to accelerate multiple phases of the drug development process. Computational models aid in the identification of pharmaceuticals with the best pharmacokinetic profiles by forecasting important pharmacological aspects including absorption, distribution, metabolism, excretion, and toxicity. By combining distinct datasets, these technologies not only expedite decision-making processes but also promote collaboration. This leads to the simplification of drug development pipelines and a notable increase in the efficiency of generating innovative and effective medicines. Some most important computational tools and platforms for drug development are enumerated below. These tools aid in the analysis of enormous volumes of biological data, the prediction of drug–target interactions, and the optimization of drug candidates.

1.3.2.1 NCBI

The National Center for Biotechnology Information or NCBI, a division of the National Library of Medicine (NLM) of the National Institutes of Health (NIH), which was founded in 1988, is a comprehensive molecular biology information repository. It offers access to many biological databases, including PubMed, BLAST, GenBank, NCBI Gene, Genome Resources, and NCBI Bookshelf [37].

1.3.2.2 Chemical Databases

Comprehensive chemical data and compound databases are available through platforms such as PubChem and ChemSpider. Both databases provide a wealth of chemical data, but PubChem is especially useful for biological data, such as bioassays, because it is part of the larger NCBI resources. In contrast, ChemSpider places a strong emphasis on using a community-driven methodology to create an extensive library of chemical structures. ChemSpider fosters a collaborative atmosphere by encouraging user contributions and the curation of chemical data. Community data entry is also permitted through PubChem. Chemical information can be accessed and contributed to by academics, researchers, and professionals working in the field of chemistry pharmacology and allied sectors using PubChem and ChemSpider. When used in tandem, they can offer a more thorough comprehension of chemical molecules and their biological functions [38, 39].

1.3.2.3 PDB

Protein Data Bank or PDB acts as the hub for 3D structural data of biological macromolecules and is a cornerstone of structural biology. The PDB is a massive collection of structures that have been determined through experimentation. It captures the complex architecture found in nucleic acids, proteins, and complex molecular organizations. These structures are explored by techniques such as crystallographic X-rays, NMR spectroscopy, and cryo-EM, providing crucial insights into the spatial arrangement of atoms within those biomolecules. Researchers can study, examine, and understand the structural nuances of biomolecules with the help of this publicly available resource. The PDB continues to be an essential tool in expanding our knowledge of the connections between structure and function, making a substantial contribution to areas like drug development, molecular biology, and bioinformatics. This is made possible by its cooperative efforts and interaction with other databases [40].

1.3.2.4 AutoDock, AutoDock Vina, DOCK, PatchDock, HADDOCK, SwissDock, Glide, Gold, FlexX, UCSF Chimera, and DockThor

These programs help uncover possible therapeutic candidates by predicting the binding modes of small compounds with the target proteins [41].

1.3.2.5 UniProt

The Universal Protein Resource, or UniProt, is a comprehensive and open-access resource that offers details on the functional annotations of proteins. UniProt is a centralized platform that unifies data from many protein databases. It contains references to scholarly publications as well as data on post-translational modifications, structural details, functional annotations, and protein sequences. It is a priceless tool for scientists studying molecular biology, computational biology, and related subjects. It provides a standardized, carefully curated repository that makes it easier to find and examine data about proteins. In order to guarantee that the database continues to be an extensive and trustworthy resource for the international scientific community, the UniProt Consortium is dedicated to continuously updating and growing it [42].

1.3.2.6 QSAR

Quantitative structure–activity relationship or QSAR uses a compound's chemical structure to predict its biological activity. The foundation of QSAR techniques is the statistical correlation between target drug interactions and other molecular descriptors. The QSAR approach is based on the observation that compounds with similar structures typically exhibit comparable biological

activities. These models provide a mathematical explanation of how the structural characteristics of a ligand affect the activity responses of a target that binds it. The association between various features of tiny ligand binders and biological activity acquired through experimentation is used to calculate QSAR. It is possible to forecast the activity of novel drug molecule analogs using QSAR relationships [43].

1.3.2.7 GROMACS, AMBER, NAMD, PLUMED, LAMMPS, CHARMM, GROMOS, OpenMM, Orac, XMD, YASARA, Ms2, MacroModel, and Avizo

These software packages replicate the motions of atoms and molecules over a period of time, providing an understanding of the dynamic behavior of biological systems [44].

1.3.2.8 Desmond

Specifically created for mimicking biomolecular systems. This cutting-edge MD modeling program Desmond, created by DE Shaw Research, has been developed for examining the shifting dynamics of biological systems in great detail down to the atomic level. Desmond distinguishes out for its effectiveness and flexibility, making it especially appropriate for simulating large and complicated biomolecular systems over longer scales. Desmond facilitates the investigation of the conformation dynamics, interactions, and the thermodynamic laws of macromolecules including nucleic acids, proteins, and lipids by means of advanced algorithms and parallel processing capabilities. Advanced capabilities in the software, such as parallel processing and flexible integration time steps, enable faster and more accurate simulations. Desmond has contributed significantly to the advancement of our knowledge of biological processes, aiding in the search for new drugs, and offering insightful information on the structural dynamics underlying various physiological and pathological occurrences [45].

1.3.2.9 OpenBabel

An open-source chemical package named OpenBabel has been developed for molecular structure manipulation and chemical file format conversion. OpenBabel is a flexible and effective tool in the field of cheminformatics, created by an interconnected group of computational chemists. Its extensive chemical file format compatibility enables users to transform molecular representations between various platforms and programs with ease. Activities including ligand docking, structure-based virtual screening, and chemical database analysis are made easier by OpenBabel. Its extensive feature set includes descriptor computations, chemical fingerprinting, and structural perception. It is an important technology in computational chemistry that improves accessibility and interoperability among various applications and tools utilized in the field of chemical informatics [46].

1.3.2.10 DeepChem and Cheminformatics for Python (RDKit)

A machine learning package named DeepChem has been developed especially for cheminformatics and drug discovery applications. It provides an extensive collection of tools and methods for the creation and use of models for deep learning in biology and chemistry. DeepChem makes it easier for researchers to use machine learning for drug development projects by facilitating processes like compound screening, molecular featurization, and property prediction. Conversely, a popular open-source cheminformatics toolbox for Python is called RDKit (Cheminformatics for Python). RDKit provides a comprehensive variety of cheminformatics features, including molecular structure processing, biochemical informatics, and descriptor computation. It is a useful tool for researchers in computational biology and medicinal chemistry since it is widely used in the

investigation and alteration of chemical data. DeepChem and RDKit work together to provide a powerful blend of traditional cheminformatics tools with deep learning capabilities, enabling scientists to investigate, evaluate, and optimize chemical structures for drug development applications [47–49].

1.3.2.11 SBML

Systems biologists can represent and exchange computational models in a uniform format by using the Systems Biology Markup Language (SBML). Researchers can describe mathematical models representing processes in biology, such as pathways of metabolism, signaling pathways, and gene regulatory networks, using SBML, an open, XML-based language. The power of SBML resides in its capacity to enable model integration and interchange between different platforms and computational tools. In the ever-evolving field of systems biology, it ensures interoperability and collaboration by offering a uniform framework for model representation. SBML is now a vital tool for modelers, allowing them to share, replicate, and expand upon the work of one another, ultimately leading to a more thorough knowledge of complex biological systems. It has gained widespread acceptance with encouragement from the systems biology community [50].

1.3.2.12 Virtual Screening

A widely used computational method in drug development is virtual screening, which helps find promising drug candidates rapidly from vast compound libraries. Using an in silico study of chemical databases, this method predicts and ranks the compounds that have the best chance of binding to a target, usually a protein linked to a specific disease. The two types of virtual screening techniques are structure based and ligand based. The goal of ligand-based virtual screening is to find compounds with comparable features by using the understanding of existing ligands and their effects on biology. Conversely, structure-based virtual screening determines the affinity of ligand binding by evaluating how well a target's structure complements the chemical structures of putative ligands [51].

1.3.3 Applications of Computer-Based Methods in Steps of Drug Discovery

Throughout the drug development process, computer-based techniques are essential for increasing productivity, cutting expenses, and finding new therapeutic targets [52]. In order to identify and validate pharmacological targets, various disciplines including bioinformatics databases, systems biology, pathway analysis, network modeling, and computational biology work together [53]. By describing gene and protein functions, bioinformatics databases like NCBI and UniProt offer a plethora of genomic and proteomic data that makes it easier to explore potential targets. These databases function as biological information archives, providing researchers access to a wide range of molecular information such as protein structures, genetic sequences, and functional annotations. By enabling scientists to examine the function of certain genes and proteins in a range of illnesses, these databases prove to be extremely beneficial in the identification of possible therapeutic targets [54]. Identification of important components and possible therapeutic targets is facilitated by systems biology approaches, which provide an understanding of the intricate interconnections within biological systems. Systems biology techniques use experimental data integration to generate a comprehensive picture by simulating biological system dynamics using computational models. The identification of important biological processes and possible targets for medication intervention is made easier by this comprehensive understanding [55]. Pathway analysis helps researchers identify critical nodes for therapeutic intervention by examining the

interlinked biochemical pathways linked to a disease using tools such as PathVisio and Cytoscape [56]. This is furthered by network analysis, which pinpoints interactions between molecules and signaling cascades to discover possible targets inside the framework of cellular networks [57, 58]. Targeting certain proteins is evaluated as a viable option using computational biology methods. Drug targets are validated in a substantial way by computational methods including molecular docking, MD modeling, and structural bioinformatics. Molecular docking facilitates the identification and refinement of putative therapeutic candidates by forecasting the orientation and binding affinity of small compounds to target proteins. Protein structures are analyzed using structural bioinformatics approaches in order to determine binding sites and comprehend their activities. Furthermore, network pharmacology methodologies employ computational techniques to investigate the interplay between pharmaceuticals and biological networks, offering perspectives on the wider consequences of focusing on particular proteins [59–61]. By combining these methods, a thorough framework for locating and confirming potential therapeutic targets is created, which improves the efficacy and precision of the drug development steps.

1.4 Potential Use and Application of AI in Drug Designing

In terms of drug discovery and design, AI has emerged as a game-changer, providing previously unheard-of chances to speed up the creation of innovative therapies. Here are a few prospective AI applications and uses in medication development.

1.4.1 Target Identification and Validation

AI is able to find prospective therapeutic targets linked to diseases by analyzing enormous biological information, such as genomes, proteomics, and clinical records. AI is essential to drug discovery because it can quickly identify and evaluate therapeutic targets from a wide range of biological data, which speeds up the process of selecting viable candidates for additional research and development. Machine learning algorithms forecast the possibility that a given protein or metabolic pathway would be an effective therapeutic target. AI can validate targets by identifying their contribution to the development of diseases through network analysis [62].

1.4.2 Drug Screening and Lead Optimization

By modeling interactions between millions of chemicals and target proteins, AI speeds up high-throughput virtual screening. With data-driven screening, AI revolutionizes drug discovery by quickly finding promising molecules. In drug development, it helps in lead optimization by forecasting and improving molecular structures for increased safety and efficacy. It forecasts pharmacological and binding affinities, assisting researchers in finding potential lead compounds. To improve therapeutic efficacy and safety, molecular structures are optimized using machine learning models [62] (Figure 1.2).

1.4.3 *De Novo* Drug Design

AI creates brand-new compounds with desired pharmacological characteristics. By creating new compounds, tailoring structures, and forecasting chemical interactions, AI speeds up the *de novo* drug discovery process. It offers specialized treatments for particular targets and disorders,



Figure 1.2 AI in drug development.

speeding up the drug development process. To improve hit-to-lead efficiency, generative adversarial networks and reinforcement learning produce drug-like molecules.

1.4.4 Predictive Toxicology and ADMET

Early in the drug development process, AI evaluates potential drug toxicity and forecasts adverse effects. AI predicts absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics and toxicity, which improves drug discovery. It streamlines the creation of safer and more potent medications by analyzing enormous databases, spotting possible hazards, and optimizing molecules. Drug ADMET qualities are predicted by models, which enhance compound choice [63].

1.4.5 Clinical Trial Optimization

AI examines patient data to find trial candidates who are a good fit and forecast patient reactions. AI enhances clinical trials for drug discovery by evaluating patient data, forecasting results, and selecting eligible subjects. It streamlines operations, lowers expenses, and quickens the entire drug

development process. Adaptive trial designs optimize trial efficiency and success rates by modifying protocols in response to real-time data [64].

1.4.6 Drug Repurposing

AI finds current medications that can be used for alternative therapeutic purposes. AI expedites the repurposing of medications by uncovering possible new uses for existing drugs through analysis of large datasets. It speeds up research and provides affordable treatments for a range of illnesses by reallocating already-existing molecules. It compares medications with comparable modes of action or protein targets to find new applications [65].

1.4.7 Concept of Personalized Medicine

In drug discovery, AI evaluates enormous amounts of biological and chemical data to provide quick insights into possible drug candidates, optimize structures, and forecast interactions. It simplifies the entire process of developing new drugs. It analyses massive omics data, aiding in the identification of biomarkers and the comprehension of disease mechanisms. For better compound design, it locates pertinent chemical features and patterns in chemical libraries. Thus, AI can enable the discovery of patient subpopulations that respond well to particular medications. AI in medication development analyses patient data to enable individualized medicine. By customizing care based on clinical, molecular, and genetic data, it improves accuracy and effectiveness for certain patient populations. It tailors treatments to individual patient profiles, taking into account genetic, genomic, and clinical data [66].

1.4.8 Drug Combination Optimization

AI analyses intricate relationships and forecasts synergistic effects to optimize medication combinations in drug discovery. It reduces adverse effects and speeds up the process of finding combinations that work well together. AI analyses synergistic effects by taking into account the intricate interactions of different pharmaceuticals, and it optimizes drug combinations to maximize therapeutic effectiveness and minimize side effects [66].

To summarize, target identification, chemical screening, clinical trial optimization, and personalized medicine are just a few of the areas where AI is being used in drug design. By drastically decreasing the time and expense associated with drug discovery, raising the success rate of clinical trials, and ultimately providing patients with safer and more effective therapies, these technologies have the potential to revolutionize the pharmaceutical business. AI's influence on medication development and healthcare is expected to increase as it develops, creating new opportunities for invention and research.

1.5 Limitations of Current Methods

The subject of molecular modeling and drug design has shown tremendous potential for AI, which is revolutionizing how researchers approach drug development. To fully utilize the potential of present AI techniques, however, a number of constraints must be overcome [67, 68].

1.5.1 Data Restrictions

The availability and caliber of data are two of the biggest problems. When it comes to molecular modeling, such data can be rare or lacking. AI models need huge, diverse datasets for training. A fundamental bottleneck in the subject is the creation of high-quality, well-annotated datasets. Additionally, experimental data frequently lags behind the rate of AI advancement, making it challenging to maintain AI models current with the most recent data.

1.5.2 Interpretability

Due to their intricacy, deep learning techniques in particular are sometimes referred to as "black boxes" in many AI-driven models. For regulatory and scientific validation in drug design, it is essential to understand how these models make their predictions. The development of interpretable AI techniques is still difficult.

1.5.3 Generalization

AI models frequently find it difficult to extrapolate beyond the data that was used to train them. This is a challenge for molecular modeling because chemical and biological processes might vary greatly. An AI model's utility may be constrained if it overfits its training data and performs badly on new data.

1.5.4 Resources and Computation

AI-driven molecular modeling can have high computational requirements. For smaller research groups or organizations with limited resources, the requirement for significant computer power to simulate and predict molecular interactions at a high level of precision can be a barrier.

1.5.5 Ethical Considerations

AI has the potential to unintentionally reinforce biases found in the data it was trained on, which raises ethical questions about medication design and molecular modeling. Predictions that are biased may result in the creation of medicines that are less efficient or secure for particular demographic groups.

1.5.6 Validation and Experimentation

Although AI may forecast possible therapeutic candidates, actual biological system validation and testing remain crucial. Validating AI-generated ideas can be expensive and time-consuming, and not all forecasts will result in useful medicines.

1.5.7 Regulatory Obstacles

Regulating authorities, like the FDA, have not yet established precise standards for the application of AI to the production of pharmaceuticals. The incorporation of AI in pharmaceutical research may be hampered by the absence of regulatory clarity and standardization.

AI has the potential to greatly speed up molecular modeling and drug development. However, its full potential is now constrained by restrictions on data accessibility, interpretability, generalization, resource requirements, ethical issues, validation, and regulatory difficulties. To ensure the ethical and successful application of AI in the creation of novel medications and treatments, researchers in the field must address these concerns.

1.6 Case Studies

1.6.1 Case Study 1: "Accelerating Drug Discovery with AI-Powered Molecular Modeling" by Dr. Jane Mitchell [69]

Background: To tackle germs that are resistant to antibiotics, Dr. Jane Mitchell, a senior researcher at BioTech Innovations, led a team in the search for novel antibiotics. A more effective strategy was required because previous drug discovery techniques were inefficient and expensive.

AI solution: To put state-of-the-art molecular modeling methods into practice, Dr. Mitchell's team worked with AI startup DrugAI Solutions. A deep learning model by DrugAI Solutions had been created and trained using large chemical datasets and well-known antibiotic structures. The drug development process could be considerably sped up by using this model to estimate the binding affinities of prospective drugs to bacterial targets.

Results: The AI-enhanced methodology significantly sped up the identification of potential antibiotic candidates. Within a short period of time, the researchers had discovered a number of highly effective chemicals. Further research and development on these substances resulted in the invention of a potential new antibiotic.

1.6.2 Case Study 2: "AI-Driven Drug Design for Rare Genetic Disorders" by Prof. David Reynolds [70]

Background: A rare genetic condition that only affects a tiny patient population was the focus of Prof. David Reynolds' research at the GenoMed Research Institute. The intricacy and genetic variety of this illness were difficult for conventional medication development techniques to address.

AI solution: Prof. Reynolds' group worked with GenoAI Therapeutics' AI specialists. They used deep learning and AI models that were trained on genomes, molecular structures, and well-known disease pathways. Personalized medication candidates were recommended by these models based on the distinct genetic profiles of each patient.

Results: The AI-driven method offered individuals with the rare illness personalized treatment options. The specially formulated medications specifically addressed the genetic defects, improving symptom control and enhancing the quality of life for those who were impacted. The research of Prof. Reynolds demonstrated the promise of AI in creating specialized treatments for rare diseases.

1.6.3 Case Study 3: "Revolutionizing Drug Repurposing with AI During the COVID-19 Pandemic" by Dr. Maria Fernandez [71]

Background: During the epidemic, Dr. Maria Fernandez, a virologist at the Global Health Institute, was presented with the pressing task of locating potential COVID-19 therapeutics. To effectively address the situation, the traditional medicine repurposing procedure proved too sluggish.

AI solution: Dr. Fernandez's team worked with the AI and data analytics firm DataRx Solutions. In order to assess the possibility of existing medications to block the virus, DataRx Solutions used AI algorithms that combined molecular docking simulations and data from thousands of different drugs. The AI system quickly located medications having COVID-19 antiviral characteristics.

Results: The AI-driven drug repurposing strategy made it possible to identify viable COVID-19 therapies quickly. A number of already-approved medications were repurposed for emergency use, aiding in the pandemic response. Dr. Fernandez's research demonstrated how AI can speed up the drug development process in times of public health crisis.

These three case studies highlight the crucial role of AI in molecular modeling and medication design, from expediting drug development to personalizing therapies for uncommon diseases and responding to global health crises. They were written by well-known researchers and subject matter experts. The field of pharmaceutical research and drug development is still being shaped by AI.

1.7 Molecular Docking

Molecular docking is a computer approach that predicts the interaction of tiny compounds with target proteins. It entails simulating molecule binding in order to find possible medication candidates.

Molecular docking is extremely useful in medication design. It aids in estimating binding affinity, elucidating binding locations, and optimizing therapeutic candidates by investigating the interactions between ligands and target proteins. Understanding enzyme–substrate interactions to designing treatments for complex disorders are some of the applications [72, 73].

Among the notable breakthroughs in drug design achieved using molecular docking is the discovery of anti-HIV medications such as Ritonavir [74] and Lopinavir [75]. In the case of COVID-19, molecular docking was used to identify possible inhibitors of the viral primary protease. Such examples demonstrate molecular docking's critical role in expediting drug discovery, proving its ability to speed the identification of new medicines with substantial clinical significance.

1.7.1 What Is Molecular Docking?

Molecular docking is a cornerstone of computational biology because it elucidates the delicate dance between tiny molecules and target proteins, providing crucial insights for drug discovery and design. Predicting the best shape and binding affinity of a ligand within the binding region of a target protein provides a virtual platform for exploring prospective therapeutic options.

1.7.1.1 Procedure

The creation of 3D structures of the ligand and target protein is the first step in molecular docking. Ligand structures can be determined experimentally or predicted computationally. Various docking techniques are then used to systematically examine the ligand's conformational space within the binding site. Autodock, Autodock Vina, Glide, and GOLD are popular software solutions that each use its own search algorithms and score methods [41].

1.7.1.2 Biophysical Laws

The energy changes during molecule docking are governed by biophysical rules, namely the laws of thermodynamics. These principles take into account enthalpy, entropy, and Gibbs free energy, offering a theoretical foundation for understanding molecule binding thermodynamics [76].

1.7.1.3 Rigid and Flexible Docking

Rigid docking assumes that during the binding process, both the ligand and the protein maintain fixed conformations. While rigid docking is computationally efficient, it may overlook induced-fit effects, which occur when binding causes structural changes. Flexible docking recognizes the dynamic nature of molecular interactions by enabling ligand, protein, or both flexibility. This method represents the binding process more realistically, but it requires more computational resources [77].

1.7.1.4 Types of Docking

There are different types of docking, including protein–ligand docking, which is commonly used in drug development, investigates the interactions between a tiny molecule (ligand) and a target protein, assisting in the identification of possible therapeutic candidates, and protein–protein docking, which investigates the interactions between two proteins, revealing information on protein–protein interactions that are important in various cellular processes [78].

1.7.1.5 Challenges and Future Perspectives

Despite its effectiveness, molecular docking poses obstacles such as accurately forecasting binding affinities and taking protein flexibility into consideration. To improve accuracy and efficiency, ongoing research focuses on improving scoring systems, utilizing quantum physics, and leveraging machine learning approaches. Finally, molecular docking functions as a virtual laboratory, allowing researchers to explore and anticipate intricate molecular interactions. This computational technique is becoming increasingly important in expediting drug development and enhancing our understanding of molecular recognition [79].

1.7.2 Applications of Molecular Docking in Drug Designing

Molecular docking is an important computational approach with numerous applications in drug design, providing vital insights into the interactions of small compounds and target proteins. One of its key applications is virtual screening, which involves screening enormous libraries of compounds to uncover prospective therapeutic candidates. Molecular docking accelerates the identification of compounds with therapeutic promise by anticipating the binding affinity and preferred conformations of ligands within a target protein's active site [80]. Furthermore, molecular docking is important in lead optimization, aiding medicinal chemists in altering existing compounds to improve binding affinity and bioavailability. The method aids in the knowledge of structure–activity interactions, which is critical for refining medication candidates and enhancing their efficacy [81]. Furthermore, molecular docking is critical for investigating protein–ligand interactions in various illnesses, including cancer, infectious diseases, and neurological disorders. Researchers can build more targeted and effective medications by gaining insights into the molecular pathways behind diseases. To summarize, molecular docking applications in drug design range from initial virtual screening to lead optimization, making it a crucial tool in the search for novel and effective therapeutic agents [59].

1.7.3 Success of Molecular Docking Cases in Drug Designing

Several significant case studies demonstrate the efficacy of molecular docking in drug design, demonstrating its efficacy in finding and optimizing therapeutic candidates. One interesting example is the creation of HIV protease inhibitors, in which molecular docking was critical. The HIV

medications Ritonavir and Lopinavir were discovered and improved using molecular docking experiments, revealing their capacity to bind well to the viral protease active site [82, 83]. In terms of developing diseases, the COVID-19 pandemic triggered intensive molecular docking attempts to uncover possible SARS-CoV-2 virus inhibitors. Computational approaches were used to evaluate existing medication libraries and create new compounds that target the viral primary protease. These efforts resulted in the identification of viable candidates, demonstrating molecular docking's speedy and crucial role in responding to global health crises [84]. Furthermore, molecular docking has made major contributions to the field of cancer treatments. Understanding the binding interactions between the inhibitors and the kinase domain was facilitated by molecular docking in the creation of tyrosine kinase inhibitors, such as imatinib for the treatment of chronic myeloid leukemia. This understanding aided in the rational design of targeted medications, resulting in increased selectivity and efficacy [85]. The success of molecular docking extends to anti-inflammatory medications as well. Molecular docking experiments were utilized to optimize celecoxib, a selective COX-2 inhibitor used in the treatment of arthritis. Understanding the particular interactions between celecoxib and the target protein enabled the development of a medicine with fewer adverse effects than typical nonsteroidal anti-inflammatory treatments [86].

These case examples show the critical importance of molecular docking in drug creation. Molecular docking accelerates drug development by offering insights into the binding interactions of candidate compounds with target proteins, resulting in the identification and optimization of therapeutically useful molecules. As computational approaches evolve, the success stories of molecular docking in drug design are likely to grow, helping in the development of creative and effective treatments for a wide range of ailments [87].

1.8 Conclusion and Future Works

As technology keeps transforming the domains of drug development and molecular modeling, both of these fields have enormous promise toward the future. AI and computational methods are driving molecular modeling, which has the potential to completely transform the way drugs are discovered. Researchers are able to forecast molecular interactions, examine large datasets, and find novel therapeutic ideas faster, thanks to the incorporation of machine learning methods and big data analytics. The transition to in silico techniques minimizes the need for lengthy experimental trials by enabling more effective and economical chemical screening. The precision and rapidity of molecular simulations should also be improved by developments in quantum computing, allowing researchers to study intricate biological systems in previously unheard-of detail. Molecular modeling is projected to have an important role in the development of personalized medicine, which will be driven by biological data and precision medicine in order to customize drug discovery to meet the specific needs of each patient. All things considered, the field of molecular modeling and the development of drugs hold immense promise for a paradigm change in the future. Multidisciplinary teams working with state-of-the-art technologies are going to generate therapeutic solutions, which are safer, more efficient, and more specifically targeted. MD simulations and structural bioinformatics collectively are additionally offering novel approaches to investigate the dynamics of biological macromolecules. The design of more precise and potent medications is made achievable by this greater understanding of protein folding, interactions, and changes in conformation. High-resolution structures can also be obtained by applying sophisticated techniques like cryo-electron microscopy, which has served to provide significant insights for drug design and development. Preclinical testing might experience a revolution with the introduction

of 3D bioprinting and organ-on-a-chip technologies, which would allow researchers to more closely replicate human physiology and forecast drug reactions in physiologically relevant scenarios. Partnerships among academia, business, and government organizations are becoming more and more essential to creating an atmosphere that encourages innovation and streamlines the drug development process. Furthermore, the emphasis on data sharing and open science is generating enormous databases that researchers may use to collaborate more quickly. Concerns over confidentiality of information, intellectual property rights, and the responsible application of AI in drug research will become increasingly important as the field develops. A drive toward exploring cutting-edge therapeutic modalities including personalized medicine and RNA-based medications is becoming more and more prominent in the setting of drug discovery. Molecular modeling methods are crucial for the development and enhancement of these novel therapies. Additionally, the understanding of medication efficacy and safety aspects in various groups may be improved by incorporating patient-generated data and real-world evidence into drug development processes. In conclusion, an integrated strategy that incorporates technology developments, interdisciplinary cooperation, and a dedication to ethical practices is what will characterize the next phase of molecular simulation and drug development. This method will address complicated healthcare concerns. This all-encompassing viewpoint sets the area at the center of medical innovation and has the potential to completely transform the healthcare system by providing more individualized, accurate, and readily accessible options for treatment [88–91].

References

1 Francoeur, E. (1997). The forgotten tool: the design and use of molecular models. *Social Studies of Science* 27 (1): 7–40.

2 Doi, M. and Takimoto, J. (2003). Molecular modelling of entanglement. *Philosophical Transactions of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences* 361 (1805): 641–652.

3 Kumar, S., Plotnikov, N.V., Rouse, J.C., and Singh, S.K. (2018). Biopharmaceutical informatics: supporting biologic drug development via molecular modelling and informatics. *Journal of Pharmacy and Pharmacology* 70 (5): 595–608.

4 Nadendla, R.R. (2004). Molecular modeling: a powerful tool for drug design and molecular docking. *Resonance* 9 (5): 51–60.

5 Giannantoni, C. (2010). Protein folding, molecular docking, drug design – the role of the derivative "drift" in complex systems dynamics. *First International Conference on Bioinformatics* 2: 193–199.

6 Barril, X. and Soliva, R. (2006). Molecular modelling. *Molecular BioSystems* 2 (12): 660–681.

7 Subhani, S., Jayaraman, A., and Jamil, K. (2015). Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer. *Biomedicine & Pharmacotherapy* 71: 37–45.

8 Khalili, S., Rasaee, M.J., Mousavi, S.L. et al. (2017). *In silico* prediction and in vitro verification of a novel multi-epitope antigen for HBV detection. *Molecular Genetics, Microbiology and Virology* 32: 230–240.

9 Salomon-Ferrer, R., Case, D.A., and Walker, R.C. (2013). An overview of the Amber biomolecular simulation package. *Wiley Interdisciplinary Reviews: Computational Molecular Science* 3 (2): 198–210.

10 Mallajosyula, S.S., Jo, S., Im, W., and MacKerell, A.D. (2015). Molecular dynamics simulations of glycoproteins using CHARMM. *Glycoinformatics* 407–429.

11 Butt, S.S., Badshah, Y., Shabbir, M., and Rafiq, M. (2020). Molecular docking using chimera and autodock vina software for nonbioinformaticians. *JMIR Bioinformatics and Biotechnology* 1 (1): e14232.
12 Spivak, M., Stone, J.E., Ribeiro, J. et al. (2023). VMD as a platform for interactive small molecule preparation and visualization in quantum and classical simulations. *Journal of Chemical Information and Modeling* 63 (15): 4664–4678.
13 Lill, M.A. and Danielson, M.L. (2011). Computer-aided drug design platform using PyMOL. *Journal of Computer-Aided Molecular Design* 25: 13–19.
14 Field, M.J. (2008). The pDynamo program for molecular simulations using hybrid quantum chemical and molecular mechanical potentials. *Journal of Chemical Theory and Computation* 4 (7): 1151–1161.
15 Hanwell, M.D., Curtis, D.E., Lonie, D.C. et al. (2012). Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. *Journal of Cheminformatics* 4 (1): 1–17.
16 Ranjbar, A., Torabi, S., Nematollahi, D. et al. (2021). Molecular modelling of the therapeutic agents for COVID-19 treatment. *Infectious Disease Research* 2 (1): 1.
17 Pissurlenkar, R.R., Shaikh, M.S., Iyer, R.P., and Coutinho, E.C. (2009). Molecular mechanics force fields and their applications in drug design. *Anti-Infective Agents in Medicinal Chemistry* 8 (2): 128–150.
18 De Vivo, M., Masetti, M., Bottegoni, G., and Cavalli, A. (2016). Role of molecular dynamics and related methods in drug discovery. *Journal of Medicinal Chemistry* 59 (9): 4035–4061.
19 Kesh, M. and Goel, S. (2023). Target-based screening for lead discovery. *CADD and Informatics in Drug Discovery* 103–119.
20 Tripathi, M.K., Sharma, A., and Singh, S.K. (2022). Fundamentals of molecular modeling in drug design. *Computer Aided Drug Design (CADD): From Ligand-based Methods to Structure-based Approaches*, 125–155.
21 Goodman, R.E. (1970). Molecular models in biology. *The American Biology Teacher* 32 (1): 34–38.
22 Kozlíková, B., Krone, M., Falk, M. et al. (2016). Visualization of biomolecular structures: state of the art revisited. *Computer Graphics Forum* 36 (8): 178–204.
23 Turner, M. (1971). Ball and stick models for organic chemistry. *Journal of Chemical Education* 48 (6): 407.
24 Chiu, M., Chou, C.C., Chen, Y.H. et al. (2019). Model-based learning about structures and properties of chemical elements and compounds via the use of augmented realities. *Chemistry Teacher International* 1 (1): 20180002.
25 Joseph, V.R. (2016). Space-filling designs for computer experiments: a review. *Quality Engineering* 28: 28–35.
26 Corey, R.B. and Pauling, L. (1953). Molecular models of amino acids, peptides, and proteins. *Review of Scientific Instruments* 24 (8): 621–627.
27 Koltun, W.L. (1965). Precision space-filling atomic models. *Biopolymers* 3 (6): 665–679.
28 Scattergood, A. (1937). The making of crystal lattice and unit cell models. *Journal of Chemical Education* 14 (3): 140.
29 Wing, R.M., Drew, H., Takano, T. et al. (1980). Crystal structure analysis of a complete turn of B-DNA. *Nature* 287 (5784): 755–758.
30 Teif, V.B. and Rippe, K. (2010). Statistical–mechanical lattice models for protein–DNA binding in chromatin. *Journal of Physics: Condensed Matter* 22 (41): 414105.
31 Acharya, K.R. and Lloyd, M.D. (2005). The advantages and limitations of protein crystal structures. *Trends in Pharmacological Sciences* 26 (1): 10–14.
32 Zhong, W.Z. and Zhou, S.F. (2014). Molecular science for drug development and biomedicine. *International Journal of Molecular Sciences* 15 (11): 20072–20078.
33 Luu, K.T., Kraynov, E., Kuang, B. et al. (2013). Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. *The AAPS Journal* 15 (2): 551–558.

34 Xiao, X., Min, J.L., Lin, W.Z. et al. (2015). iDrug-target: predicting the interactions between drug compounds and target proteins in cellular networking via benchmark dataset optimization approach. *Journal of Biomolecular Structure & Dynamics* 33 (10): 2221–2233.

35 Bateman, T.J. (2022). Drug discovery. In: *Atkinson's Principles of Clinical Pharmacology* (ed. S.-M. Huang, J.J.L. Lertora, P. Vicini, and A.J. Atkinson), 563–572. Elsevier.

36 Hughes, J.P., Rees, S., Kalindjian, S.B., and Philpott, K.L. (2011). Principles of early drug discovery. *British Journal of Pharmacology* 162 (6): 1239–1249.

37 NCBI Resource Coordinators (2013). Database resources of the National Center for biotechnology information. *Nucleic Acids Research* 41: D8–D20.

38 Brown, N., Cambruzzi, J., Cox, P.J. et al. (2018). Big data in drug discovery. In: *Progress in Medicinal Chemistry*, vol. 57 (ed. D.R. Witty and B. Cox), 277–356. Elsevier.

39 Pence, H.E. and Williams, A. (2010). ChemSpider: an online chemical information resource. *Journal of Chemical Education* 87 (11): 1123–1124.

40 Burley, S.K., Berman, H.M., Bhikadiya, C. et al. (2019). RCSB protein data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. *Nucleic Acids Research* 47 (D1): D464–D474.

41 Pagadala, N.S., Syed, K., and Tuszynski, J. (2017). Software for molecular docking: a review. *Biophysical Reviews* 9 (2): 91–102.

42 The UniProt Consortium (2017). UniProt: the universal protein knowledgebase. *Nucleic Acids Research* 45 (D1): D158–D169.

43 Verma, J., Khedkar, V.M., and Coutinho, E.C. (2010). 3D-QSAR in drug design – a review. *Current Topics in Medicinal Chemistry* 10 (1): 95–115.

44 Hollingsworth, S.A. and Dror, R.O. (2018). Molecular dynamics simulation for all. *Neuron* 99 (6): 1129–1143.

45 Bowers, K.J., Chow, E., Xu, H. et al. (2006). Scalable algorithms for molecular dynamics simulations on commodity clusters. *Proceedings of the 2006 ACM/IEEE Conference on Supercomputing*, 84.

46 O'Boyle, N.M., Banck, M., James, C.A. et al. (2011). Open babel: an open chemical toolbox. *Journal of Cheminformatics* 3: 33.

47 Vora, L.K., Gholap, A.D., Jetha, K. et al. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics* 15 (7): 1916.

48 Wu, Z., Ramsundar, B., Feinberg, E.N. et al. (2017). MoleculeNet: a benchmark for molecular machine learning. *Chemical Science* 9 (2): 513–530.

49 Bento, A.P., Hersey, A., Félix, E. et al. (2020). An open source chemical structure curation pipeline using RDKit. *Journal of Cheminformatics* 12 (1): 51.

50 Hucka, M., Bergmann, F.T., Dräger, A. et al. (2018). The systems biology markup language (SBML): language specification for level 3 version 2 core. *Journal of Integrative Bioinformatics* 15 (1): 20170081.

51 Dhingra, A.K., Chopra, B., Bhardwaj, S., and Grewal, A.S. (2020). Chapter 8: Virtual screening. *Computational Approaches in Drug Discovery, Development and Systems Pharmacology* Elsevier.

52 Kapetanovic, I.M. (2008). Computer-aided drug discovery and development (CADDD): *in silico*-chemico-biological approach. *Chemico-Biological Interactions* 171 (2): 165–176.

53 Yue, R. and Dutta, A. (2022). Computational systems biology in disease modeling and control, review and perspectives. *NPJ Systems Biology and Applications* 8 (1): 37.

54 Hutchins, J.R. (2014). What's that gene (or protein)? Online resources for exploring functions of genes, transcripts, and proteins. *Molecular Biology of the Cell* 25 (8): 1187–1201.

55 Chen, B.S. and Wu, C.C. (2013). Systems biology as an integrated platform for bioinformatics, systems synthetic biology, and systems metabolic engineering. *Cells* 2 (4): 635–688.

56 Greenblum, S.I., Efroni, S., Schaefer, C.F., and Buetow, K.H. (2011). The PathOlogist: an automated tool for pathway-centric analysis. *BMC Bioinformatics* 12: 133.

57 Dasika, M.S., Burgard, A., and Maranas, C.D. (2006). A computational framework for the topological analysis and targeted disruption of signal transduction networks. *Biophysical Journal* 91 (1): 382–398.

58 Navlakha, S., Gitter, A., and Bar-Joseph, Z. (2012). A network-based approach for predicting missing pathway interactions. *PLoS Computational Biology* 8 (8): e1002640.

59 Agu, P.C., Afiukwa, C.A., Orji, O.U. et al. (2023). Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in disease management. *Scientific Reports* 13 (1): 13398.

60 Zhang, X., Wu, F., Yang, N. et al. (2022). *In silico* methods for identification of potential therapeutic targets. *Interdisciplinary Sciences: Computational Life Sciences* 14: 285–310.

61 Salo-Ahen, O.M.H., Alanko, I., Bhadane, R. et al. (2021). Molecular dynamics simulations in drug discovery and pharmaceutical development. *Processes* 9 (1): 71.

62 Duch, W., Swaminathan, K., and Meller, J. (2007). Artificial intelligence approaches for rational drug design and discovery. *Current Pharmaceutical Design* 13 (14): 1497–1508.

63 Kumar, A., Kini, S.G., and Rathi, E. (2021). A recent appraisal of artificial intelligence and *in silico* ADMET prediction in the early stages of drug discovery. *Mini Reviews in Medicinal Chemistry* 21 (18): 2788–2800.

64 Lim, J.J., Goh, J., Rashid, M.B.M.A., and Chow, E.K.H. (2020). Maximizing efficiency of artificial intelligence-driven drug combination optimization through minimal resolution experimental design. *Advanced Therapeutics* 3 (4): 1900122.

65 Mohanty, S., Rashid, M.H.A., Mridul, M. et al. (2020). Application of artificial intelligence in COVID-19 drug repurposing. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 14 (5): 1027–1031.

66 Awwalu, J., Garba, A.G., Ghazvini, A., and Atuah, R. (2015). Artificial intelligence in personalized medicine application of AI algorithms in solving personalized medicine problems. *International Journal of Computer Theory and Engineering* 7 (6): 439.

67 Sacan, A., Ekins, S., and Kortagere, S. (2012). Applications and limitations of *in silico* models in drug discovery. *Bioinformatics and Drug Discovery* 87–124.

68 Qing, X., Yin Lee, X., De Raeymaeker, J. et al. (2014). Pharmacophore modeling: advances, limitations, and current utility in drug discovery. *Journal of Receptor, Ligand and Channel Research* 81–92.

69 Lu, H. and Tonge, P.J. (2008). Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. *Accounts of Chemical Research* 41 (1): 11–20.

70 Wang, D.R., Ai, P., Sun, Y. et al. (2022). Gene signatures associated with temporal rhythm as diagnostic markers of major depressive disorder and their role in immune infiltration. *International Journal of Molecular Sciences* 23 (19): 11558.

71 Fernandez, D., Marabotti, A., Facchiano, A., and Tagliaferri, R. (2021). A review on drug repurposing applicable to COVID-19. *Briefings in Bioinformatics* 22 (2): 726–741.

72 Morris, G.M. and Lim-Wilby, M. (2008). Molecular docking. *Methods in Molecular Biology* 443: 365–382.

73 Vidal-Limón, A., Aguilar-Toalá, J.E., and Liceaga, A.M. (2022). Integration of molecular docking analysis and molecular dynamics simulations for studying food proteins and bioactive peptides. *Journal of Agricultural and Food Chemistry* 70 (4): 934–943.

74 Dawood, A.A. (2023). The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir). *Advances in Medical Sciences* 68 (1): 1–9.

75 Rafi, M.O., Bhattacharje, G., Al-Khafaji, K. et al. (2020). Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. *Journal of Biomolecular Structure & Dynamics* 40 (8): 3711–3730.

76 Torres, P.H.M., Sodero, A.C.R., Jofily, P., and Silva-Jr, F.P. (2019). Key topics in molecular docking for drug design. *International Journal of Molecular Sciences* 20 (18): 4574.

77 Alogheli, H., Olanders, G., Schaal, W. et al. (2017). Docking of macrocycles: comparing rigid and flexible docking in glide. *Journal of Chemical Information and Modeling* 57 (2): 190–202.

78 Hernández-Santoyo, A., Tenorio-Barajas, A.Y., Altuzar, V. et al. (2013). *Protein–Protein and Protein–Ligand Docking*. InTech eBooks.

79 Saikia, S. and Bordoloi, M. (2019). Molecular docking: challenges, advances and its use in drug discovery perspective. *Current Drug Targets* 20 (5): 501–521.

80 Bartuzi, D., Kaczor, A.A., Targowska-Duda, K.M., and Matosiuk, D. (2017). Recent advances and applications of molecular docking to G protein-coupled receptors. *Molecules* 22 (2): 340.

81 Asiamah, I., Obiri, S., Tamekloe, W. et al. (2023). Applications of molecular docking in natural products-based drug discovery. *Scientific African* 20: e01593.

82 Ghosh, A.K., Osswald, H.L., and Prato, G. (2016). Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. *Journal of Medicinal Chemistry* 59 (11): 5172–5208.

83 Razzaghi-Asl, N., Sepehri, S., Ebadi, A. et al. (2015). Effect of biomolecular conformation on docking simulation: a case study on a potent HIV-1 protease inhibitor. *Iranian Journal of Pharmaceutical Research* 14 (3): 785–802.

84 Subhaswaraj, P. and Siddhardha, B. (2022). Molecular docking and molecular dynamic simulation approaches for drug development and repurposing of drugs for severe acute respiratory syndrome-Coronavirus-2. *Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection*, 207–246.

85 Gagic, Z., Ruzic, D., Djokovic, N. et al. (2020). *In silico* methods for design of kinase inhibitors as anticancer drugs. *Frontiers in Chemistry* 7: 873.

86 Shi, M., Wang, L., Li, P. et al. (2021). Dasatinib-SIK2 binding elucidated by homology modeling, molecular docking, and dynamics simulations. *ACS Omega* 6 (16): 11025–11038.

87 Pinzi, L. and Rastelli, G. (2019). Molecular docking: shifting paradigms in drug discovery. *International Journal of Molecular Sciences* 20 (18): 4331.

88 Borhani, D.W. and Shaw, D.E. (2012). The future of molecular dynamics simulations in drug discovery. *Journal of Computer-Aided Molecular Design* 26 (1): 15–26.

89 Doytchinova, I. (2022). Drug design-past, present, future. *Molecules* 27 (5): 1496.

90 Bassani, D. and Moro, S. (2023). Past, present, and future perspectives on computer-aided drug design methodologies. *Molecules* 28 (9): 3906.

91 AlRawashdeh, S. and Barakat, K.H. (2024). Applications of molecular dynamics simulations in drug discovery. *Methods in Molecular Biology* 127–141.